2234. Outcomes by Age and Gender from a Global Phase 3 Study of Delafloxacin (DLX) in Community-Acquired Bacterial Pneumonia (CABP)

BACKGROUND: Delafloxacin (DLX) is a fluoroquinolone, approved in the United States for treatment of ABSSSI. DLX has no preclinical signals for QT prolongation and has no QT prolongation in a validated challenge study. Risk of QT prolongation is a consideration in antibiotic selection for elderly hos...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Open Forum Infect Dis
Autori principali: Madej, Andrzej, Pullman, John, Popescu, Monica, Quintas, Megan, Lawrence, Laura, Li, Yang, Cammarata, Sue
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2019
Soggetti:
Abstracts
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6810084/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofz360.1912
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi